Editas Medicine (EDIT) Projected to Announce Earnings on Monday

Editas Medicine (NASDAQ:EDIT) is expected to release its Q3 2026 results before the market opens on Monday, November 9th. Analysts expect the company to announce earnings of ($0.21) per share and revenue of $4.54 million for the quarter. Interested persons may visit the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Tuesday, November 10, 2026 at 4:00 PM ET.

Editas Medicine (NASDAQ:EDIT) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.12. Editas Medicine had a negative return on equity of 196.63% and a negative net margin of 157.32%. The firm had revenue of $11.89 million for the quarter, compared to analyst estimates of $2.85 million. On average, analysts expect Editas Medicine to post ($0.80) EPS for the current fiscal year and ($0.81) EPS for the next fiscal year.

Editas Medicine Stock Performance

Shares of NASDAQ:EDIT opened at $2.67 on Monday. The company has a market capitalization of $410.06 million, a P/E ratio of -3.56 and a beta of 2.00. Editas Medicine has a 52-week low of $1.66 and a 52-week high of $3.94. The company has a 50-day simple moving average of $2.76 and a 200 day simple moving average of $2.67.

Wall Street Analysts Forecast Growth

EDIT has been the topic of a number of recent research reports. Guggenheim upgraded Editas Medicine from a “neutral” rating to a “buy” rating and set a $5.00 target price on the stock in a research note on Wednesday, September 23rd. Wells Fargo & Company upgraded Editas Medicine from an “equal weight” rating to an “overweight” rating and increased their target price for the company from $4.00 to $6.00 in a research report on Thursday, October 8th. Weiss Ratings upgraded Editas Medicine from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. LADENBURG THALM/SH SH assumed coverage on shares of Editas Medicine in a report on Tuesday, August 18th. They set a “buy” rating and a $6.00 price objective on the stock. Finally, Wall Street Zen upgraded shares of Editas Medicine from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. Six research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $5.83.

Editas Medicine Company Profile

Editas Medicine, Inc is a biotechnology company focused on developing genomic medicines using CRISPR-based gene-editing technologies. The company’s research platforms include CRISPR/Cas9 and CRISPR/Cas12a, which are designed to make precise changes to DNA and potentially treat diseases caused by genetic abnormalities.

Editas Medicine’s lead investigational program is reni-cel, formerly known as EDIT-301. Reni-cel is an ex vivo gene-editing therapy intended to treat sickle cell disease and transfusion-dependent beta thalassemia by modifying a patient’s blood-forming stem cells before they are returned to the body.